Cargando…

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg(−1) wk(−1) or to a control group receiving epoetin alfa at an initial dose of 150 U kg(−1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg(−1...

Descripción completa

Detalles Bibliográficos
Autores principales: Glaspy, J A, Jadeja, J S, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Tchekmedyian, N S, Armstrong, S, O'Byrne, J, Rossi, G, Colowick, A B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364226/
https://www.ncbi.nlm.nih.gov/pubmed/12177793
http://dx.doi.org/10.1038/sj.bjc.6600465
_version_ 1782153900819742720
author Glaspy, J A
Jadeja, J S
Justice, G
Kessler, J
Richards, D
Schwartzberg, L
Tchekmedyian, N S
Armstrong, S
O'Byrne, J
Rossi, G
Colowick, A B
author_facet Glaspy, J A
Jadeja, J S
Justice, G
Kessler, J
Richards, D
Schwartzberg, L
Tchekmedyian, N S
Armstrong, S
O'Byrne, J
Rossi, G
Colowick, A B
author_sort Glaspy, J A
collection PubMed
description In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg(−1) wk(−1) or to a control group receiving epoetin alfa at an initial dose of 150 U kg(−1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg(−1) every 2 weeks or epoetin alfa, initial dose 40 000 U wk(−1). Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy. British Journal of Cancer (2002) 87, 268–276. doi:10.1038/sj.bjc.6600465 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2364226
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23642262009-09-10 Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Glaspy, J A Jadeja, J S Justice, G Kessler, J Richards, D Schwartzberg, L Tchekmedyian, N S Armstrong, S O'Byrne, J Rossi, G Colowick, A B Br J Cancer Clinical In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg(−1) wk(−1) or to a control group receiving epoetin alfa at an initial dose of 150 U kg(−1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg(−1) every 2 weeks or epoetin alfa, initial dose 40 000 U wk(−1). Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy. British Journal of Cancer (2002) 87, 268–276. doi:10.1038/sj.bjc.6600465 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-07-29 2002-08-01 /pmc/articles/PMC2364226/ /pubmed/12177793 http://dx.doi.org/10.1038/sj.bjc.6600465 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Glaspy, J A
Jadeja, J S
Justice, G
Kessler, J
Richards, D
Schwartzberg, L
Tchekmedyian, N S
Armstrong, S
O'Byrne, J
Rossi, G
Colowick, A B
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title_full Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title_fullStr Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title_full_unstemmed Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title_short Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
title_sort darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364226/
https://www.ncbi.nlm.nih.gov/pubmed/12177793
http://dx.doi.org/10.1038/sj.bjc.6600465
work_keys_str_mv AT glaspyja darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT jadejajs darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT justiceg darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT kesslerj darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT richardsd darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT schwartzbergl darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT tchekmedyianns darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT armstrongs darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT obyrnej darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT rossig darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy
AT colowickab darbepoetinalfagivenevery1or2weeksalleviatesanaemiaassociatedwithcancerchemotherapy